Variant Summary
- HGVS
- —
- Variant Type(s)
- inframe_insertion
- Evidence Items
- 31
Evidence Level Distribution
Level A: 1Level B: 22Level C: 1Level D: 7
Evidence Items
Showing CIViC evidence rows where gene = FLT3 and variant = ITD.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 5 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 5 | |
| D | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Ponatinib | 5 |
| B | Predictive | Supports | Resistance | Acute Promyelocytic Leukemia | Anthracycline Antineoplastic Antibiotic,Tretinoin | 4 |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Does Not Support | Acute Myeloid Leukemia | 4 | ||
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Lestaurtinib | 4 |
| B | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Sorafenib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Tyrphostin AG 1296 | 4 |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 4 | |
| B | Prognostic | Does Not Support | Acute Myeloid Leukemia | 4 | ||
| D | Predictive | Supports | Sensitivity/Response | Leukemia | Sunitinib,Sorafenib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Gilteritinib | 4 |
| B | Prognostic | Supports | Poor Outcome | Acute Promyelocytic Leukemia | 3 | |
| B | Predictive | Supports | Resistance | Acute Myeloid Leukemia | Tretinoin | 3 |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 3 | |
| D | Predictive | Supports | Resistance | Acute Myeloid Leukemia | Daunorubicin | 3 |
| D | Predictive | Supports | Resistance | Acute Myeloid Leukemia | SU5614 | 3 |
| A | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 3 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 3 | |
| B | Diagnostic | Supports | Positive | Acute Myeloid Leukemia | 3 | |
| B | Prognostic | Supports | Poor Outcome | Acute Myeloid Leukemia | 3 | |
| D | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Gilteritinib | 3 |
| B | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Sorafenib | 2 |
| B | Predictive | Supports | Resistance | Acute Myeloid Leukemia | Selumetinib | 2 |
| B | Prognostic | Does Not Support | Acute Myeloid Leukemia | 2 | ||
| C | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Sorafenib | 1 |